List of Figures
Figure 1: Number of Products under Development for Age Related Macular Degeneration 17
Figure 2: Number of Products under Development for Age Related Macular Degeneration – Comparative Analysis 18
Figure 3: Number of Products under Development for Diabetic Retinopathy 19
Figure 4: Number of Products under Development for Diabetic Retinopathy – Comparative Analysis 20
Figure 5: Number of Products under Development for Diabetic Macular Edema 21
Figure 6: Number of Products under Development for Diabetic Macular Edema – Comparative Analysis 22
Figure 7: Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) 23
Figure 8: Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) – Comparative Analysis 24
Figure 9: Number of Products under Development for Glaucoma, 25
Figure 10: Number of Products under Development for Glaucoma – Comparative Analysis, 26
Figure 11: Number of Products under Development by Companies - Age Related Macular Degeneration 27
Figure 12: Number of Products under Development by Companies -Diabetic Retinopathy 35
Figure 13: Number of Products under Development by Companies -Diabetic Macular Edema 37
Figure 14: Number of Products under Development by Companies - Keratoconjunctivitis sicca (Dry Eye) 41
Figure 15: Number of Products under Development by Companies - Glaucoma 45
Figure 16: Number of Products under Investigation by Universities/Institutes - Age Related Macular Degeneration 50
Figure 17: Number of Products under Investigation by Universities/Institutes - Diabetic Macular Edema 51
Figure 18: Number of Products under Investigation by Universities/Institutes - Glaucoma 52
Figure 19: Comparative Analysis by Late Stage Development - Age Related Macular Degeneration 54
Figure 20: Comparative Analysis by Clinical Stage Development - Age Related Macular Degeneration 55
Figure 21: Comparative Analysis by Early Stage Products - Age Related Macular Degeneration 56
Figure 22: Comparative Analysis by Clinical Stage Development - Diabetic Retinopathy 58
Figure 23: Comparative Analysis by Early Stage Products - Diabetic Retinopathy 59
Figure 24: Comparative Analysis by Late Stage Development - Diabetic Macular Edema 60
Figure 25: Comparative Analysis by Clinical Stage Development - Diabetic Macular Edema 61
Figure 26: Comparative Analysis by Early Stage Products - Diabetic Macular Edema 62
Figure 27: Comparative Analysis by Late Stage Development - Keratoconjunctivitis sicca (Dry Eye) 63
Figure 28: Comparative Analysis by Clinical Stage Development- Keratoconjunctivitis sicca (Dry Eye) 64
Figure 29: Comparative Analysis by Early Stage Products- Keratoconjunctivitis sicca (Dry Eye) 65
Figure 30: Comparative Analysis by Late Stage Development - Glaucoma 66
Figure 31: Comparative Analysis by Clinical Stage Development - Glaucoma 67
Figure 32: Comparative Analysis by Early Stage Products - Glaucoma 68
Figure 33: Comparative Analysis by Unknown Stage Development - Glaucoma 69
Figure 34: Assessment by Monotherapy Products - Age Related Macular Degeneration 278
Figure 35: Number of Products by Top 10 Targets - Age Related Macular Degeneration 280
Figure 36: Number of Products by Stage and Top 10 Targets - Age Related Macular Degeneration 280
Figure 37: Number of Products by Top 10 Mechanism of Actions - Age Related Macular Degeneration 288
Figure 38: Number of Products by Stage and Top 10 Mechanism of Actions - Age Related Macular Degeneration 288
Figure 39: Number of Products by Top 10 Routes of Administration - Age Related Macular Degeneration 294
Figure 40: Number of Products by Stage and Top 10 Routes of Administration - Age Related Macular Degeneration 294
Figure 41: Number of Products by Top 10 Molecule Types - Age Related Macular Degeneration 296
Figure 42: Number of Products by Stage and Top 10 Molecule Types - Age Related Macular Degeneration 296
Figure 43: Assessment by Monotherapy Products - Diabetic Retinopathy 298
Figure 44: Number of Products by Top 10 Targets - Diabetic Retinopathy 299
Figure 45: Number of Products by Stage and Top 10 Targets - Diabetic Retinopathy 299
Figure 46: Number of Products by Top 10 Mechanism of Actions - Diabetic Retinopathy 303
Figure 47: Number of Products by Stage and Top 10 Mechanism of Actions - Diabetic Retinopathy 303
Figure 48: Number of Products by Top 10 Routes of Administration - Diabetic Retinopathy 307
Figure 49: Number of Products by Stage and Top 10 Routes of Administration - Diabetic Retinopathy 307
Figure 50: Number of Products by Top 10 Molecule Types - Diabetic Retinopathy 309
Figure 51: Number of Products by Stage and Top 10 Molecule Types - Diabetic Retinopathy 309
Figure 52: Assessment by Monotherapy Products - Diabetic Macular Edema 310
Figure 53: Number of Products by Top 10 Targets - Diabetic Macular Edema 312
Figure 54: Number of Products by Stage and Top 10 Targets - Diabetic Macular Edema 312
Figure 55: Number of Products by Top 10 Mechanism of Actions - Diabetic Macular Edema 316
Figure 56: Number of Products by Stage and Top 10 Mechanism of Actions - Diabetic Macular Edema 316
Figure 57: Number of Products by Routes of Administration - Diabetic Macular Edema 319
Figure 58: Number of Products by Stage and Routes of Administration - Diabetic Macular Edema 319
Figure 59: Number of Products by Molecule Types - Diabetic Macular Edema 321
Figure 60: Number of Products by Stage and Molecule Types - Diabetic Macular Edema 321
Figure 61: Assessment by Monotherapy Products - Keratoconjunctivitis sicca (Dry Eye) 323
Figure 62: Number of Products by Top 10 Targets - Keratoconjunctivitis sicca (Dry Eye) 324
Figure 63: Number of Products by Stage and Top 10 Targets - Keratoconjunctivitis sicca (Dry Eye) 324
Figure 64: Number of Products by Top 10 Mechanism of Actions - Keratoconjunctivitis sicca (Dry Eye) 330
Figure 65: Number of Products by Stage and Top 10 Mechanism of Actions - Keratoconjunctivitis sicca (Dry Eye) 330
Figure 66: Number of Products by Top 10 Routes of Administration - Keratoconjunctivitis sicca (Dry Eye) 337
Figure 67: Number of Products by Stage and Top 10 Routes of Administration - Keratoconjunctivitis sicca (Dry Eye) 337
Figure 68: Number of Products by Molecule Types - Keratoconjunctivitis sicca (Dry Eye) 339
Figure 69: Number of Products by Stage and Molecule Types - Keratoconjunctivitis sicca (Dry Eye) 339
Figure 70: Assessment by Monotherapy Products - Glaucoma 341
Figure 71: Assessment by Combination Products - Glaucoma 342
Figure 72: Number of Products by Top 10 Targets - Glaucoma 343
Figure 73: Number of Products by Stage and Top 10 Targets - Glaucoma 343
Figure 74: Number of Products by Top 10 Mechanism of Actions - Glaucoma 350
Figure 75: Number of Products by Stage and Top 10 Mechanism of Actions - Glaucoma 350
Figure 76: Number of Products by Top 10 Routes of Administration - Glaucoma 357
Figure 77: Number of Products by Stage and Top 10 Routes of Administration - Glaucoma 357
Figure 78: Number of Products by Top 10 Molecule Types - Glaucoma 359
Figure 79: Number of Products by Stage and Top 10 Molecule Types - Glaucoma 359